Human Ehrlichiosis is an emerging tick-borne infection that became reportable to the CDC health institute, USA, in 1999.
The term Ehrlichiosis is a general designation encapsulating several tick-borne etiologic agents based on their similar clinical presentations. These obligate intracellular bacteria are both epidemiologically and etiologically distinct from one another. Known since 1935, Ehrlichia species were primarily regarded as veterinarial pathogens infecting sheep, goats, horses, cattle, and dogs. In 1953, Neorickettsia sennetsu was isolated in Japan from the first human infection, however, identification of the next human strain did not occur until 1986. At present, five strains capable of infecting humans have been identified and three (Anaplasma phagocytophilum, Ehrlichia chaffeensis and Ehrlichia ewingii) have been clinically characterized. Neither Ehrlichia canis nor Nerorickettsia sennetsu, the remaining human strains, have been sufficiently investigated.
Analytes (Measurands) marked with a * are not accredited.
(2x ACD/CPDA tube)
Ehrlichia-IgM and Ehrlichia-IgG-antibodies
(1x Serum/SST tube)
Ehrlichia/Anaplasma-DNA-PCR in blood
(2x EDTA tube)
(out of the tick)
Ehrlichia chaffeensis (Human Monocytic Ehrlichiosis = HME),
Anaplasma phagocytophilum (Human Granulocytic Ehrlichiosis = HGE) (gram-negative, obligatory intracellular in granulocytes)
Ixodes ricinus, Ixodes scapularis (deer tick)
game (e.g. deer), domestic animals, humans
Rapid onset of beginning illness with fever, chills, headache and prostration, headaches are described as “sharp, knife-like stings often originating from behind the eyes”, muscle pain, not joint pain, neurological symptoms, confusion, rarely diffuse vasculitic rash, including palms and soles (<10 %), thromboctopenia, leukopenia, elevated liver enzymes
tick bites, older people, severe illnesses (e.g.: cancer), immune suppression (children).